Jefferies Lowers PT On Somaxon Pharma To $2.50

Symbols: SOMX
Share

Jefferies & Company has lowered the price target on Somaxon Pharma (NASDAQ: SOMX) from $7 to $2.50 and maintains its Buy rating.


 
 
< Previous
Collins Stewart Upgrades VMware To Buy, $108 PT
Next >
Morgan Stanley Overweight On Penn National Gaming
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust